

Antonio D Avolio

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3027989/antonio-davolio-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

300
papers

4,622
citations

34
h-index

50
g-index

317
ext. papers

5,331
ext. citations

4.7
avg, IF

5.5
L-index

#	Paper	IF	Citations
300	A combined role for low vitamin D and low albumin circulating levels as strong predictors of worse outcome in COVID-19 patients.. <i>Irish Journal of Medical Science</i> , 2022 , 1	1.9	0
299	Ceftobiprole and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis.. <i>Journal of Chemotherapy</i> , 2022 , 1-3	2.3	
298	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0013622	5.9	2
297	Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. <i>Pharmaceuticals</i> , 2022 , 15, 630	5.2	
296	A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy. <i>Phytomedicine</i> , 2022 , 102, 154218	6.5	0
295	A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 755184	5.6	0
294	Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 750433	5.6	0
293	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> , 2021 , 22, 831	2.8	1
292	Validation and Clinical Application of a New Liquid Chromatography Coupled to Mass Spectrometry (HPLC-MS) Method for Dalbavancin Quantification in Human Plasma. <i>Separations</i> , 2021 , 8, 189	3.1	1
291	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106297	14.3	0
290	The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 665-676	5.5	2
289	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4432-4438	3.8	1
288	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
287	Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement. <i>Frontiers in Pharmacology</i> , 2021 , 12, 668843	5.6	
286	Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
285	Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3655-e3664	5.6	4
284	Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021 , 210, 105854	5.1	3

283	Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00811	3.1	
282	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 89-102	6.2	2
281	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 103-109	6.2	6
280	Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 391.e1-391.e7	6.4	45
279	Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. <i>Emerging Infectious Diseases</i> , 2021 , 27,	10.2	18
278	Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. <i>Scientific Reports</i> , 2021 , 11, 443	4.9	4
277	-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
276	Pharmacokinetics of bictegrovir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3320-3322	5.1	0
275	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. <i>Biomedicines</i> , 2021 , 9,	4.8	1
274	Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. <i>Biomedicines</i> , 2021 , 9,	4.8	1
273	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1772-1777	5.1	41
272	25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. <i>Nutrients</i> , 2020 , 12,	6.7	236
271	Antiretroviral concentrations in the presence and absence of valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1969-1971	5.1	3
270	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2977-2980	5.1	55
269	Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105908	14.3	8
268	Effect of Gender and Age on Voriconazole Trough Concentrations in Italian Adult Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020 , 45, 405-412	2.7	1
267	Impact of imipenem concentration in lung perfusate and tissue biopsy during clinical ex-vivo lung perfusion of high-risk lung donors. <i>Minerva Anestesiologica</i> , 2020 , 86, 617-626	1.9	1
266	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2020 , 14,	5.2	2

265	Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 187, 113337	3.5	2
264	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 628-639	5.1	5
263	Determination of Perampanel in Dried Plasma Spots: Applicability to Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 309-314	3.2	3
262	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 665-670	3.2	6
261	Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. <i>Scientific Reports</i> , 2020 , 10, 16178	4.9	5
260	Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. <i>Data in Brief</i> , 2020 , 33, 106445	1.2	1
259	Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 165-168	3.2	7
258	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 ,	5.9	2
257	Monoclonal antibodies with subnanomolar affinity to tenofovir for monitoring adherence to antiretroviral therapies: from hapten synthesis to prototype development. <i>Journal of Materials Chemistry B</i> , 2020 , 8, 10439-10449	7.3	2
256	Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 20, 22-27	3.4	4
255	Data on the stability of darunavir/cobicistat suspension after tablet manipulation. <i>Data in Brief</i> , 2020 , 30, 105552	1.2	6
254	Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz427	1	13
253	Novel "Matrix-Corrected Calibration" study for the detection of polyunsaturated fatty acids (PUFAs) in plasma and erythrocytes by means of a gas chromatography-mass spectrometry approach optimized to follow up long-term parental patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 176, 112764	3.5	1
252	Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofy332	1	13
251	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019 , 11,	6.6	4
250	Development of Standard Operating Protocols for the Optimization of -Based Formulations for Medical Purposes. <i>Frontiers in Pharmacology</i> , 2019 , 10, 701	5.6	9
249	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	7
248	Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C. <i>Antiviral Therapy</i> , 2019 , 24, 553-555	1.6	

247	Rhino-Orbital-Cerebral Mucormycosis after Allogeneic Hematopoietic Stem Cell Transplantation and Isavuconazole Therapeutic Drug Monitoring during Intestinal Graft versus Host Disease. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019 , 11, e2019061	3.2	5
246	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 254-255	3.2	
245	LC-MS/MS-Based Quantification of 9 Antiepileptic Drugs From a Dried Sample Spot Device. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 331-339	3.2	13
244	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 202-204	2.9	1
243	SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1035-1043	5.1	15
242	LC-MS application for therapeutic drug monitoring in alternative matrices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019 , 166, 40-51	3.5	47
241	Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 65-71	3.5	3
240	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 417-427	3.5	4
239	Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. <i>Neurocritical Care</i> , 2019 , 31, 116-124	3.3	13
238	Cannabinoids concentration variability in cannabis olive oil galenic preparations. <i>Journal of Pharmacy and Pharmacology</i> , 2018 , 70, 143-149	4.8	40
237	Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1659-1664	5.1	6
236	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 546-548	5.1	2
235	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients. <i>Infection, Genetics and Evolution</i> , 2018 , 60, 42-47	4.5	2
234	Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1380-1383	3.8	2
233	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 615-620	3.5	7
232	Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. <i>Archives of Virology</i> , 2018 , 163, 961-967	2.6	5
231	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 826-827	5.1	16
230	Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients. <i>Biomedical Chromatography</i> , 2018 , 32, e4274	1.7	5

229	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. <i>Pharmacogenomics</i> , 2018 , 19, 913-925	2.6	10
228	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1550-1556	2.9	6
227	Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. <i>Antiviral Therapy</i> , 2018 , 23, 373-377	1.6	2
226	Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 17-22	1.9	4
225	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018 , 19, 145-165	2.6	9
224	Clinical relevance of deferasirox trough levels in β -thalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 213-216	3	3
223	Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. <i>Pharmacogenomics Journal</i> , 2018 , 18, 506-515	3.5	5
222	Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 197-203	3.8	23
221	Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. <i>Pharmacogenetics and Genomics</i> , 2018 , 28, 199-206	1.9	1
220	A Common <i>mdr1</i> Gene Polymorphism is Associated With Changes in Linezolid Clearance. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 602-609	3.2	6
219	A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018 , 94, 29-35	1.7	3
218	Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis. <i>European Addiction Research</i> , 2018 , 24, 184-188	4.6	2
217	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	2
216	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy. <i>Pharmacogenomics</i> , 2018 , 19, 701-707	2.6	0
215	Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2535-2543	3.8	19
214	Deferasirox pharmacokinetic evaluation in β -thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 525-528	4.8	4
213	First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients. <i>Journal of Mass Spectrometry</i> , 2017 , 52, 187-195	2.2	16
212	Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1146-1148	3.8	3

211	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <i>Journal of Clinical Virology</i> , 2017 , 87, 30-36	14.5	5
210	Role of simeprevir plasma concentrations in HCV treated patients with dermatological manifestations. <i>Digestive and Liver Disease</i> , 2017 , 49, 705-708	3.3	1
209	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 138, 223-230	3.5	34
208	A rapid and robust UHPLC-DAD method for the quantification of amphotericin B in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 138, 142-145	3.5	3
207	Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 784-785	14.3	5
206	Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. <i>Pharmacogenomics</i> , 2017 , 18, 651-661	2.6	5
205	Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia. <i>Pharmacogenomics</i> , 2017 , 18, 607-611	2.6	1
204	Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017 , 42, 621-623	2.2	3
203	The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 965-968	3	4
202	UHPLC-MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 142, 279-285	3.5	24
201	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017 , 18, 865-880	2.6	5
200	Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1741-1744	5.1	14
199	Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 850-857	3.4	25
198	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017 , 18, 539-554	2.6	10
197	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 767-773	3.5	11
196	Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study. <i>Infection, Genetics and Evolution</i> , 2017 , 51, 167-172	4.5	3
195	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3163-3166	5.1	5
194	Matrix effect management in liquid chromatography mass spectrometry: the internal standard normalized matrix effect. <i>Bioanalysis</i> , 2017 , 9, 1093-1105	2.1	45

193	Influence of ABCB11 and HNF4B genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2846-2849	5.1	6
192	Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017 , 44, 1083-1088	3	13
191	Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1524-1530	4.8	6
190	A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 145, 718-724	3.5	14
189	Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3. <i>European Journal of Public Health</i> , 2017 , 27, 938-941	2.1	1
188	Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. <i>Infection</i> , 2017 , 45, 103-106	5.8	9
187	Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 319-321	5.1	7
186	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 355-369	6.2	19
185	Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. <i>Biomedicines</i> , 2017 , 5,	4.8	12
184	The and polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017 , 8, 88021-88033	3.3	10
183	Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. <i>Infection, Genetics and Evolution</i> , 2017 , 53, 195-198	4.5	6
182	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815	5.1	6
181	Pharmacogenomic influence on sepsis outcome in critically ill patients. <i>Infezioni in Medicina</i> , 2017 , 25, 45-49	3.6	3
180	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016 , 16, 514-518	3.5	18
179	Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 347-8	14.3	9
178	UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 129, 535-541	3.5	31
177	Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients. <i>Drugs</i> , 2016 , 76, 1161-74	12.1	21
176	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016 , 17, 561-72	2.6	13

175	UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 118, 64-69	3.5	16
174	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016 , 30, 915-20	3.5	11
173	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016 , 497, 287-92	6.5	9
172	Antihypertensive Bridge Therapy by Continuous Drug Infusion With an Elastomeric Pump in Device-Resistant Hypertension. <i>Hypertension</i> , 2016 , 67, e3-4	8.5	1
171	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. <i>Blood</i> , 2016 , 128, 3951-3951	2.2	
170	The Role of IL28B Genotype in HCV-RNA Baseline Levels. <i>Intervirology</i> , 2016 , 59, 67-68	2.5	1
169	A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4. <i>Intervirology</i> , 2016 , 59, 283-284	2.5	
168	Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir. <i>Aids</i> , 2016 , 30, 1491-3	3.5	1
167	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 307-10	1.9	8
166	Pharmacogenetics of ribavirin-induced anemia in HCV patients. <i>Pharmacogenomics</i> , 2016 , 17, 925-41	2.6	16
165	Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?. <i>Journal of Viral Hepatitis</i> , 2016 , 23, 402-3	3.4	
164	Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016 , 88, 1953-9	19.7	9
163	Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. <i>Antiviral Research</i> , 2016 , 136, 32-36	10.8	8
162	Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β -thalassaemia. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 84, 1510-1512	7.5	2
161	Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 409-11	1.6	15
160	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 117-23	14.3	21
159	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1155-7	2.8	8
158	Colistin Use in Patients With Reduced Kidney Function. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 296-306	7.4	27

157	A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 125, 369-75	3.5	96
156	Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2016 , 63, 285-6	11.6	7
155	Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 750-4	2.2	1
154	Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 324-7	14.3	6
153	Deferasirox pharmacokinetic and toxicity correlation in β -thalassaemia major treatment. <i>Journal of Pharmacy and Pharmacology</i> , 2016 , 68, 1417-1421	4.8	9
152	Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 129, 551-557	3.5	28
151	Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 749-51	2.3	4
150	Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump. <i>International Journal of Pharmaceutical Compounding</i> , 2016 , 20, 343-346	0.2	
149	Development and validation of an ultra performance liquid chromatography tandem mass method for sildenafil and N-desmethyl sildenafil plasma determination and quantification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015 , 1001, 35-40	3.2	12
148	UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 127-32	3.5	24
147	Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 657-61	14.3	8
146	An UPLC-MS/MS method coupled with automated on-line SPE for quantification of tacrolimus in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 107, 512-7	3.5	26
145	Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1167-76	5.5	7
144	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 801-8	3.8	12
143	Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. <i>Archives of Virology</i> , 2015 , 160, 2009-17	2.6	7
142	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2417-8	5.1	10
141	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 8-11	3.5	17
140	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 164-72	1.9	10

139	A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2572-5	5.1	18
138	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3074-9	5.1	10
137	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3096-9	5.1	14
136	UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 115, 443-9	3.5	9
135	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients-authors response. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3169	5.1	
134	Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. <i>Clinical Infectious Diseases</i> , 2015 , 60, 311-7	11.6	41
133	Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 205.e1-9	3.5	12
132	Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 47-55	7.5	12
131	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 318-27	3.4	19
130	ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. <i>Biomedicine and Pharmacotherapy</i> , 2015 , 69, 63-9	7.5	12
129	Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. <i>Pharmacogenomics Journal</i> , 2015 , 15, 263-71	3.5	16
128	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. <i>Antiviral Therapy</i> , 2015 , 20, 335-41	1.6	17
127	Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 695-6	3.2	2
126	Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015 , 18, 171-6	3.4	8
125	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 307-8	5.1	8
124	Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 545-9	14.3	4
123	Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 435-44	5.9	33
122	Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage. <i>Antiviral Research</i> , 2015 , 116, 45-7	10.8	5

121	SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1155-60	5.1	8
120	Combined Famd and ANOVA Investigation Leads to Significant Association Between the hOCT1/ABCB1 Diplotype and Both Efficacy and Tolerability in Patients Affected By Chronic Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 4838-4838	2.2	
119	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. <i>Infezioni in Medicina</i> , 2015 , 23, 367-9	3.6	3
118	Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 260-3	3.4	23
117	Pharmacokinetics of the co-administration of boceprevir and St John® wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1911-5	5.1	9
116	A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 94, 65-70	3.5	8
115	Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4042-7	5.9	12
114	Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1760-6	5.1	5
113	Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. <i>Antiviral Research</i> , 2014 , 109, 7-14	10.8	12
112	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9	5.1	4
111	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 241-5	5.1	24
110	Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 88, 66-70	3.5	35
109	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3061-6	5.1	34
108	Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools. <i>Journal of Hepatology</i> , 2014 , 61, 178-9	13.4	3
107	The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon. <i>Journal of Infection</i> , 2014 , 69, 81-7	18.9	20
106	Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 90, 119-26	3.5	20
105	Therapeutic drug monitoring of intracellular anti-infective agents. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 101, 183-93	3.5	15
104	UPLC-MS/MS method for quantification of the azathioprine metabolites 6-mercaptopguanosine and 6-methylmercaptopurine riboside in peripheral blood mononuclear cells. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 98, 271-8	3.5	21

103	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014 , 108, 44-7	10.8	6
102	A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?. <i>Current Drug Metabolism</i> , 2014 , 15, 581-98	3.5	43
101	Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E. <i>Journal of Medical Virology</i> , 2014 , 86, 1845-50	19.7	11
100	Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2586-8	5.1	1
99	Cerebrospinal fluid penetration of tigecycline. <i>Scandinavian Journal of Infectious Diseases</i> , 2014 , 46, 69-72		15
98	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. <i>Pharmacogenomics</i> , 2014 , 15, 1281-6	2.6	6
97	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. <i>BMC Cancer</i> , 2014 , 14, 184	4.8	61
96	No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. <i>Aids</i> , 2014 , 28, 1993-5	3.5	1
95	Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 410-2	3.2	9
94	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. <i>Antiviral Research</i> , 2014 , 102, 35-43	10.8	25
93	Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. <i>Antiviral Research</i> , 2014 , 106, 105-10	10.8	9
92	Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. <i>Current HIV Research</i> , 2014 , 12, 339-46	1.3	7
91	Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. <i>Infezioni in Medicina</i> , 2014 , 22, 107-11	3.6	3
90	External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients. <i>AAPS Journal</i> , 2013 , 15, 308-15	3.7	2
89	Determination of telaprevir in plasma of HCV-infected patients by HPLC-UV. <i>IUBMB Life</i> , 2013 , 65, 800-54.7		5
88	Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. <i>Antiviral Research</i> , 2013 , 100, 114-9	10.8	25
87	Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 2013 , 45, 882-4		0
86	Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?. <i>Journal of Hepatology</i> , 2013 , 59, 633-4	13.4	7

85	Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. <i>International Journal of Antimicrobial Agents</i> , 2013 , 41, 590-1	14.3	27
84	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013 , 936, 42-7	3.2	30
83	Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. <i>Journal of Clinical Virology</i> , 2013 , 56, 167-9	14.5	12
82	A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013 , 78-79, 217-23	3.5	21
81	Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis: data from the clinical practice in a single-centre cohort. <i>Antiviral Therapy</i> , 2013 , 18, 87-94	1.6	6
80	Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, e118-9	3.1	2
79	Ultra performance liquid chromatography PDA method for determination of tigecycline in human plasma. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 853-8	3.2	10
78	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1686-8	5.1	10
77	Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1938-9	5.1	12
76	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 907-10	5.1	18
75	Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 482-4	5.1	3
74	Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D. <i>Liver International</i> , 2013 , 33, 580-5	7.9	31
73	Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. <i>Journal of Viral Hepatitis</i> , 2013 , 20, e11-9	3.4	30
72	Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1840-3	5.9	31
71	Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. <i>Journal of Chemotherapy</i> , 2013 , 25, 376-8	2.3	9
70	Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 293-300	1.9	29
69	HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 59, 109-16	3.5	53
68	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 66, 376-80	3.5	24

67	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 134-40	3.8	29
66	Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. <i>Infection</i> , 2012 , 40, 69-75	5.8	5
65	F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy. <i>Digestive and Liver Disease</i> , 2012 , 44, S42	3.3	5
64	Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2645-9	5.1	30
63	Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012 , 4, e2012007	3.2	1
62	Inpatient and outpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 232-5	3.2	29
61	Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 604-6	3.2	5
60	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 722-8	3.2	30
59	Anidulafungin for <i>Candida glabrata</i> infective endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4552-3	5.9	16
58	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 165-70	3.2	37
57	Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , 2012 , 26, 1529-33	3.5	33
56	Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. <i>Blood</i> , 2012 , 120, 4903-4903	2.2	1
55	Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1340-5	5.1	8
54	Ceftriaxone bone penetration in patients with septic non-union of the tibia. <i>International Journal of Infectious Diseases</i> , 2011 , 15, e415-21	10.5	18
53	Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011 , 25, 1437-9	3.5	19
52	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011 , 16, 499-504	1.6	9
51	Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. <i>Malaria Journal</i> , 2011 , 10, 141	3.6	11
50	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011 , 54, 2278-9	11.2	25

49	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 779-88	3.5	55
48	Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 885-9	5.1	4
47	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 192-200	5.1	14
46	Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 224-5	5.1	15
45	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1932-4	5.1	7
44	Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2976-8	5.9	53
43	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65	1.9	38
42	Raltegravir penetration in seminal plasma of healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2744-5	5.9	13
41	Is peritoneal fluid a sanctuary site for HIV?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2052-3	5.1	1
40	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5242-50	5.9	63
39	Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3408-13	5.9	45
38	Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. <i>Aids</i> , 2010 , 24, 931-2	3.5	11
37	2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4. <i>Journal of Hepatology</i> , 2010 , 52, S463	13.4	6
36	A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 86-92 ²	3.2	19
35	Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 590-6	3.1	50
34	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010 , 24, 1064-6	3.5	103
33	Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 396, 791-8	4.4	64
32	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 52, 774-80	3.5	62

31	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5	5.1	9
30	Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant. <i>American Journal of Transplantation</i> , 2009 , 9, 2429-34	8.7	8
29	New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1721-6	3.2	82
28	Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 104-9	3.2	36
27	Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 431-2	3.1	17
26	Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 793-805	6.2	31
25	Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?. <i>Clinical Drug Investigation</i> , 2008 , 28, 305-11	3.2	0
24	A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. <i>Journal of Chromatographic Science</i> , 2008 , 46, 524-8	1.4	36
23	The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 919-24	5.1	47
22	Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. <i>Clinical Infectious Diseases</i> , 2008 , 46, 146-7	11.6	29
21	Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1066-71	5.9	15
20	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1356-64	5.1	9
19	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 384-7	5.1	6
18	Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1222-5	11.6	73
17	Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1113-7	5.1	10
16	A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 90-4	3.2	9
15	An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 662-9	3.2	99
14	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 848, 374-8	3.2	22

13	HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 859, 234-40	3.2	77
12	Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1654-5	11.6	9
11	Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 483-5	5.1	1
10	An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 110-5	3.2	11
9	Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006 , 20, 1977-9	3.5	23
8	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 127-30	3.2	46
7	Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3966-9	5.9	60
6	Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 280-1	5.1	33
5	Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. <i>Aids</i> , 2004 , 18, 577-8	3.5	7
4	In vitro activity of propolis against <i>Streptococcus pyogenes</i> . <i>Letters in Applied Microbiology</i> , 2000 , 31, 174-7	2.9	76
3	Calcyclin gene expression modulation by medroxyprogesterone acetate. <i>Biochemical Pharmacology</i> , 1997 , 54, 299-305	6	0
2	L-histidine/medroxyprogesterone acetate interaction modulates human breast cancer cell growth and progesterin receptor expression in vitro. <i>Pharmacological Research</i> , 1997 , 35, 119-22	10.2	0
1	Enhancement of calcyclin gene RNA expression in squamous cell carcinoma of the oral mucosa, but not in benign lesions. <i>Journal of Oral Pathology and Medicine</i> , 1997 , 26, 206-10	3.3	16